Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Learn
Share
Network
Benefit
Delivering Affordable Innovation Through Global Partnerships
USAIC has created an ecosystem committed to driving a global dialogue on BioPharma & Healthcare innovation, attracting a diverse mix of senior industry professionals and catalyzing partnerships, new ideas, networks and regulatory reform. This unique platform creates mutually beneficial opportunities and relationships for the global Life Sciences & Healthcare industry.
USAIC to honor:
USAIC to honor:
Awarded to Dr. Andrew Plump for his vision and longstanding deep commitment to catalyzing industry-academic partnerships, interdisciplinary translational biomedical research & development, and innovation-based solutions for a healthier world.
Andrew Plump, M.D., Ph.D., is the President of Research & Development (R&D) at Takeda and serves as a member of the company’s Board of Directors.
Dr. Plump joined Takeda to oversee the company’s global R&D organization in 2015. Early in his Takeda tenure he orchestrated a multi-year strategic and cultural transformation that resulted in a renewed focus on innovation, streamlined global footprint, prioritized therapeutic areas of focus, a rich network of partnerships and a modality-diverse portfolio of newly approved and promising late-stage development experimental therapies. He also championed efforts to establish an exciting and sustainable early development and research pipeline, founded on strong translational science. Over the last several years of Dr. Plump’s leadership, Takeda has embraced scientific advances and the emergence of data and digital technology to build a renewed, diverse and highly innovative pipeline of investigational medicines that are expected to provide meaningful benefits to patients.
Prior to Takeda, Dr. Plump served as senior vice president, Research & Translational Medicine, deputy to the president of R&D at Sanofi, based in Paris, France. Before Sanofi, he served as vice president, Worldwide Cardiovascular Research head at Merck, where he had direct responsibility for cardiovascular research, preclinical development and translational sciences.
Dr. Plump received his M.D. from the University of California, San Francisco (UCSF), his Ph.D. in cardiovascular genetics with Dr. Jan Breslow at Rockefeller University and his B.S. from the Massachusetts Institute of Technology (MIT). He completed a residency in Internal Medicine and a fellowship in Medical Genetics at UCSF. Following his clinical training, Dr. Plump trained as a Howard Hughes and Stanley J. Sarnoff postdoctoral fellow with Dr. Marc Tessier-Lavigne at UCSF, concurrently assuming faculty responsibilities as an adjunct clinical instructor in the Department of Medical Genetics.